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ABSTRACT: As over 6 million people are infected with Chagas disease and
only limited therapeutic options are available, there is an urgent need for
novel drugs. The involvement of cyclic nucleotide phosphodiesterases (PDE)
in the lifecycle and biological ﬁtness of a number of protozoan parasites has
been described and several of these enzymes are thought to be viable drug
targets. Within this context, a PDE-focused library was screened for its ability
to aﬀect the viability of Trypanosoma cruzi parasites. 5-(3-(Benzyloxy)-4-
methoxyphenyl)-2-isopropyl-4,4-dimethyl-2,4-dihydro-3H-pyrazol-3-one (4),
previously reported as a human PDE4 inhibitor, was identiﬁed as a hit. Upon
optimization on three positions of the phenylpyrazolone scaﬀold, 2-isopropyl-
5-(4-methoxy-3-(pyridin-3-yl)phenyl)-4,4-dimethyl-2,4-dihydro-3H-pyrazol-
3-one (34) proved to be the most active compound against intracellular forms
of T. cruzi (pIC50 = 6.4) with a 100-fold selectivity with respect to toxicity
toward human MRC-5 cells. Evaluation on diﬀerent life stages and clinically relevant T. cruzi strains revealed that the
phenylpyrazolones are not active against the bloodstream form of the Y strain but show submicromolar activity against the
intracellular form of the Y- and Tulahuen strains as well as against the nitro-drug-resistant Colombiana strain. In vitro screening
of phenylpyrazolones against TcrPDEB1, TcrPDEC, and TcrCYP51 showed that there was a poor correlation between enzyme
inhibition and the observed phenotypic eﬀect. Among the most potent compounds, both TcrCYP51 and non-TcrCYP51
inhibitors are identiﬁed, which were both equally able to inhibit T. cruzi in vitro.
■ INTRODUCTION
Trypanosoma cruzi, a protozoan parasite, is the causative agent
of Chagas disease.1 This disease was once only endemic in
Latin-America, however as human mobility increases it is now
spreading into other areas such as Europe, Australia, Northern-
America, and Middle America.2−5 It is estimated that
approximately 6 million people are currently infected world-
wide.6 Of all individuals carrying this infection about 30% will
develop a progressive chronic cardiomyopathy and another
10% will develop digestive, neurological, or mixed clinical
symptoms.7
While the current drugs benznidazole (Radanil) (1, Figure
1) and nifurtimox (Lampit) (2) are quite eﬀective in curing the
disease in its initial acute phase, eﬃcacy of these drugs during
the chronic disease phase is much less evident.8 The recent
BENEFIT trial on the eﬃcacy of benznidazole (1) in patients
with chronic Chagas disease reported that the cardiac
deterioration was not signiﬁcantly impaired, despite the
signiﬁcantly reduced serum parasitemia.9 Moreover, besides
their limited eﬃcacy in the chronic phase, both benznidazole
(1) and nifurtimox (2) exhibit severe side eﬀects, require long
drug administration, and are ineﬀective against naturally
resistant T. cruzi strains.10,11 Despite these risks and limitations
and its relatively high disease burden, the drug discovery
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pipeline for Chagas disease does not provide high hopes for a
novel treatment on a short term notice.12
Mainly academic groups have been trying to ﬁll this
innovation gap, although there are some collaborations with
industry in public-private partnerships.13−15 In this paper, we
describe part of the research of the EU-funded, public-private
consortium PDE4NPD (www.PDE4NPD.eu), that focuses on
35-cyclic nucleotide phosphodiesterases (PDEs) as targets
against a number of neglected tropical diseases. PDEs are
enzymes that hydrolyze phosphodiesterase bonds such as those
found in the intracellular (IC) cyclic nucleotides cAMP and
cGMP and thereby are involved in the control of IC
signalling.16 Level control of the secondary messengers
cAMP and cGMP is essential in various cell functions, for
example diﬀerentiation, proliferation, and regulation of
osmotic stress in a variety of cells, including parasites.17−19
In kinetoplastida, four diﬀerent PDE families have been
identiﬁed, namely PDEA-PDED, which show high homology
between the diﬀerent kinetoplastid species.20
Previously, the eﬀectiveness of targeting parasite PDEs has
been shown for Giardia lamblia and the closely related
protozoan parasite Trypanosoma brucei.21−23 An inhibitor of
two parasite PDEs TbrPDEB1 and TbrPDEB2, NPD-001 (3,
Figure 1; also disclosed as a human PDE4 inhibitor), elevated
IC cAMP levels, disrupted regulation of the cell cycle, and
ultimately lead to death of the trypanosomes.24,25 Moreover,
the importance of PDEs in controlling cAMP levels and
thereby regulating cellular processes such as regulatory volume
control in T. cruzi has been reported.26−28 One of the PDE
family members, TcrPDEC, has subsequently been suggested
as an antiparasitic drug target.29
As PDE inhibition seems a viable approach toward new
treatments against kinetoplastids, an in-house library of known
PDE inhibitors was screened against T. cruzi in phenotypic
assays. In this screening eﬀort, the human PDE4 inhibitor
(hPDE4 pIC50 = 6.8) NPD-0583 (4, Figure 1), previously also
reported by Orrling et al. as TbrPDEB1 inhibitor (pIC50 =
5.4), was identiﬁed as a hit against the IC form of T. cruzi
(pIC50 = 5.0).
21 On the basis of these results, three positions of
the core scaﬀold were selected for optimization: the benzyloxy
moiety R1, the pyrazolone nitrogen substituent R2, and the
methoxy moiety on R3 (5, Figure 2).
■ CHEMISTRY
For hit optimization and SAR analysis, we designed a synthetic
route that allowed eﬃcient modiﬁcation at all three positions.
Orrling et al.21 reported a similar route for this chemical class;
however, some small modiﬁcations were made to the ﬁrst three
steps.
In the ﬁrst step, the acid chloride of benzoic acid 6 was
formed and subsequently condensed with the separately
formed lithium enolate of methylisobutyrate (Scheme 1).
The resulting β-keto-ester 7 was used crude for the ring closure
with hydrazine to give key intermediate 8 in 89% yield over
two steps. With dihydropyrazolone 8 at hand, the ﬁrst
substituent of choice could be introduced on the pyrazolone
nitrogen (R2) via an alkylation with the desired aliphatic
bromine. These N-alkylated intermediates (9−21, Scheme 1)
were used in either a Suzuki reaction to install the ﬁnal aryl
substituent (R1) (22−47, 51−64, Scheme 1) or in a Buchwald
reaction to install aliphatic amines (48−50). The third and
ﬁnal position (R3) could be modiﬁed after demethylation of
intermediate 11 (5-(3-bromo-4-methoxyphenyl)-2-isopropyl-
4,4-dimethyl-2,4-dihydro-3H-pyrazol-3-one), followed by sub-
sequent O-alkylation. The newly obtained O-alkyl intermedi-
ates (66−74, Scheme 1) were used in a Suzuki reaction to
install the ﬁnal aryl substituent (R1), (75−83).
■ PHARMACOLOGY AND PARASITOLOGY
All compounds were initially tested for their trypanocidal
activity against IC forms of T. cruzi, Tulahuen CL2, β-
galactosidase strain (drug sensitive strain, (discrete typing
units, DTU VI)) as well as for cytotoxicity on MRC-5SV2 cells
(human lung ﬁbroblasts). In-depth pharmacological proﬁling
was performed using IC amastigotes from the naturally highly
and moderately nitro-drug-resistant Colombiana strain (DTU
I) and from the Y-strain (DTU II), respectively. Additionally,
bloodstream trypomastigotes (BT) of the Y-strain obtained
from infected Swiss Webster mice were used. Toxicity proﬁling
was done using primary cell cultures of mouse embryonic
cardiac cells. TcrCYP51 inhibition assays were performed
Figure 1. Current drugs against T. cruzi: benznidazole (1), nifurtimox (2), PDE inhibitor NPD-001 (3), which is able to kill T. brucei, and
phenyldihydropyrazolone NPD-0583 (4) hit from the phenotypic screening.
Figure 2. Hit molecule NPD-0583 (4) from which the phenyl-
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using CYP51 (full length) from the Tulahuen strain using the
ﬂuorescence based assay reported by Riley et al.30 The catalytic
domains of Tcr(Y)PDEC (aa 270−614) and Tcr(Y)PDEB1
(aa 564−918) were ampliﬁed by PCR from full length
sequences and cloned (NdeI and XhoI) into the vector
pET28a.31 Protein production and puriﬁcation of both
Tcr(Y)PDE_CDs were performed following the same
protocol. Escherichia coli strain BL21(DE3)*pLysS was trans-
formed with either plasmid pET28aTcr(Y)PDEC_270-614 or
pET28aTcr(Y)PDEB1_564-918 and the resulting recombinant
strains were grown in 2YT medium at 37 °C. A typical
puriﬁcation yielded about 10 mg Tcr(Y)PDEC_CD and 7 mg
Tcr(Y)PDEB1_CD from a 1 L cell culture. PDE activity assays
are performed using the PDELight HTS cAMP phosphodies-
terase kit (Lonza, Walkersville, USA).
■ RESULTS AND DISCUSSION
Compounds from an in-house PDE-focused library were
screened in vitro for their trypanocidal eﬀect against the IC
form of T. cruzi (Tulahuen CL2 strain transfected with β-
galactosidase gene) and their toxicity on human lung
ﬁbroblasts (MRC-5). NPD-0583 (4) was identiﬁed as a “hit”
from which the phenyl-pyrazolone scaﬀold (5, Figure 2) was
derived for further optimization. As the catechol moiety of
NPD-0583 (4) is a chemotype commonly observed in human
PDE4 inhibitors, and human PDE oﬀ-target activity is
preferably avoided, the ﬁrst analogues synthesized did not
contain the 3-benzyloxy moiety. Instead, the phenyl group was
attached directly to the pyrazolone-phenyl scaﬀold, leading to
compound 22 (Table 1), which has a similar activity as NPD-
0583 (4) with a pIC50 of 5.1. Moreover, substituted phenyl
analogues (23−32, Table 1) showed a similar or improved
activity over NPD-0583 (4, Figure 1). While introduction of a
2-ﬂuorophenyl (23) led to diminished activity (pIC50 < 4.2),
both the 3- and 4-ﬂuorophenyl analogues (24−25, Table 1)
showed a substantial increase in activity over the unsubstituted
phenyl (22) with pIC50 values around 6. Introduction of a 3-
and 4-chloro- or methoxyphenyl ring (26−29, Table 1) also
increased activity compared to the unsubstituted phenyl
analogue (22) with pIC50 values around 5.5. The most active
substituted phenyl derivative was the 3-cyanophenyl-substi-
tuted compound (30) with a pIC50 of 6.4, while the 4-
cyanophenyl analogue (31, Table 1) had an activity of 5.6.
Substituting both the 3- and 4-position, as seen with
dimethoxyphenyl 32 did not improve activity (pIC50 = 4.9,
Table 1).
Introduction of pyridines on the R1 position led to mixed
results. The 2-pyridine analogue 33 (Table 1) showed almost
no activity, while the 3- and 4-pyridine substituted phenyl-
dihydropyrazolones (34−35) were amongst the most potent
analogues with pIC50 values of 6.4 and 5.8, respectively.
Introduction of a ﬂuorine on the 4-position of the 3-pyridine
(36) did not aﬀect the activity, while substitution with larger
substituents such as 4-methyl (37), 4-methoxy (38), and 4-
cyano (39) resulted in a 10-fold decrease in potency (Table 1).
Introduction of a methyl group on the 6-position of the 3-
pyridinyl moiety (40) decreased activity even further. Adding a
small substituent on the 3-position of 4-pyridines resulted in a
signiﬁcant increase in activity; the 3-ﬂuoro-4-pyridinyl
analogue (41, Table 1) is for example very active with a
pIC50 of 6.3, while the 3-methyl-4-pyridinyl (42) analogue has
a pIC50 of 6.4, as opposed to 5.8 for the unsubstituted 4-
pyridinyl (35). These activities are similar to 3-pyridinyl-
phenylpyrazolone 34 (pIC50 = 6.4), the most potent
compound in the series obtained so far. Introduction of
other heterocycles such as a pyrimidine (43, Table 1), indole
(44), isoquinoline (45), furan (46), and thiophene (47)
generally caused a large decrease in activity, exception being
pyrimidine 43 which only showed a minor decrease in activity
(pIC50 = 6.0) compared to the 3-pyridine substituted
phenylpyrazolone 34.
Scheme 1a
aReagents and Conditions: (a) (i): (COCl2), DMF, DCM, 2 h, rt, (ii): methylisobutyrate, LDA, THF, −78 °C to rt; (b) N2H4·H2O, EtOH, 18 h,
rt; 89% Over Two Steps; (c) NaH, R2-Br, DMF, 2 h, 50 °C; 70−95%; (d) R1-B(OH2), Pd(dppf)Cl2·CH2Cl2, 1 M Na2CO3, DME, 1 h, 120 °C μW;
14−94%; (e) 11, BBr3, DCM, 18 h, rt; 90%; (f) R3-Br, DMF, 3 h, 50 °C; 17−96%; (g) R1-B(OH2), Pd(dppf)Cl2·CH2Cl2, 1 M Na2CO3, DME, 1 h,
120 °C μW; 30−94%
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Table 1. Phenotypic Activity against IC Amastigotes of T. cruzi (Tulahuen Strain) and on MRC-5 Cell Growth by
Phenyldihydropyrazolones with Modiﬁcation on the R1 Position
aAll reported values are within a standard deviation of ±0.2.
Table 2. Phenotypic Activity against IC Amastigotes of T. cruzi (Tulahuen Strain) and on MRC-5 Cell Growth by
Phenyldihydropyrazolones with Modiﬁcation on the R2 Position
aAll reported values are within a standard deviation of ±0.2.
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To extend the SAR on this position, several non-aromatic
heterocycles (48−50, Table 1) were introduced on the R1
position, but the activity was 100-fold lower than the most
potent hits obtained so far, showing that an aromatic feature is
preferred on this position.
In the obtained set of phenyldihydropyrazolones with
diﬀerent R1 substituents, several compounds show potencies
around 6.4 (pIC50). Since 3-pyridinyl 34 (NPD-0227) has the
lowest clog P, low MRC-5 toxicity, and does not contain a
ﬂuorine moiety that has the potential risk of nucleophilic
aromatic substitution, SAR exploration on the R2 and R3
position (5, Figure 2) was further done using this moiety on
the R1 position. Initially, the N-unsubstituted phenyldihy-
dropyrazolone (51) as well as diﬀerent sizes of branched and
unbranched aliphatic chains (52−58, Table 2) were synthe-
sized and evaluated on the R2 position. While the non-
substituted compound (51, Table 2) is virtually inactive with
an pIC50 of 4.4, adding aliphatic R2 substituents substantially
increased activity. While introduction of a methyl group (52,
Table 2) resulted only in a minor increase, the N-ethyl
substituted dihydropyrazolone (53) showed a 10-fold increase
in parasitic activity (pIC50 = 5.4). This activity was further
increased by adding another methyl moiety, as in the N-
isopropyl substituted dihydropyrazolone NPD-0227 (34,
Table 2), which has a pIC50 of 6.4. Analogues containing
larger alkyl groups on the R2 position, such as cyclo-
propylmethyl 54, cyclobutylmethyl 55, isopentyl 56, and
cyclopentyl 57 all showed submicromolar antiparasitic activity
(Table 2). Introduction of the larger cycloheptyl (58, Table 2)
decreased the activity against T. cruzi while increasing the
cytotoxicity. Introduction of a polar 2-hydroxyethyl group (59)
on the pyrazolone nitrogen did not improve the activity
compared to the unsubstituted dihydropyrazolone 51 (Table
2). Introducing butanenitrile (60) or pentanenitrile (61) led to
improved activities compared to the unsubstituted pyrazolone
51 with pIC50 values of 5.4 and 5.9, respectively. To establish if
aromatic moieties are allowed on the R2 position, three
methylpyridines (62−64, Table 2) were introduced. The
observed activities were substantially higher than for the
unsubstituted dihydropyrazolone (51). The 4-pyridinylmethyl
(64, pIC50 = 5.8) showed higher activity than the 2- and 3-
pyridinylmethyl analogues (62, 63). However, the antiparasitic
activity of the 4-pyridinylmethyl-substituted pyrazolone 64
(pIC50 = 5.8) was well below the activity of the isopropyl
derivative 34. Overall, variations on the R2-position did not
improve the activity signiﬁcantly compared to the isopropyl
dihydropyrazolone (34, Table 2). Although the cyclo-
propylmethyl (54), cyclobutylmethyl (55), and cyclopentyl
(57) dihydropyrazolones reached similar potencies as the iso-
propyl (34), the mild increase in toxicity observed with these
compounds as well as higher clog P values resulted in the
decision to continue the SAR exploration on R3 (5, Figure 2)
with the N-isopropyl moiety on the R2 position (34).
The ﬁnal position that was varied on the phenylpyrazolone
scaﬀold was the R3 position (5, Figure 2). At ﬁrst, small
aliphatic moieties up to 5 carbons (75−79, Table 3) were
introduced. While the smaller ethyl (75) and isopropyl (76)
substituents showed a quite drastic drop in activity compared
to the original methyl-substituted phenylpyrazolone (34)
(Table 3), the slightly larger cyclopropylmethyl (77), cyclo-
butylmethyl (78), and cyclopentyl (79) are equipotent to the
methoxy analogue (34) with pIC50 values around 6.3.
Installing the larger benzyl group (80) caused a larger drop
in activity (pIC50 of 5.1).
In order to decrease the log P, several aliphatic moieties with
heteroatoms were installed. However, neither acetonitrile (81),
tetrahydrofuran (82), or tetrahydropyran (83) moieties proved
to provide a positive eﬀect on activity (Table 3) as all these
derivatives displayed a pIC50 of 5.0 or lower. Hence, the
methoxy group, already present in the original hit, remains the
substituent of choice.
After SAR-investigation on the three selected positions (5,
Figure 2), the most optimal compound within these series
contained a 3-pyridinyl moiety on R1, an isopropyl group on
the R2 position, and a methyl substituent on the R3 position.
The most active hit, the cyclopentyl-substituted phenyl-
dihydropyrazolone (57, Table 2), was ∼32 fold more active
than the original hit (4, Figure 1). Nonetheless, it was decided
to continue further studies with the 3-pyridinyl phenyl-
dihydropyrazolone (34, NPD-0227) as it showed a slightly
lower cytotoxicity (∼100 fold selectivity) and generally had
more favorable physicochemical properties compared to the
Table 3. Phenotypic Activity against IC Amastigotes of T. cruzi (Tulahuen Strain) and on MRC-5 Cell Growth by
Phenyldihydropyrazolones with Modiﬁcation on the R3 Position
aAll reported values are within a standard deviation of ±0.2.
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other equipotent analogues. The role of physicochemical
properties was further investigated by plotting the T. cruzi
pIC50’s against clog P, clog S, and TPSA. However, correlations
were all poor with R2’s below 0.15 (Table S1, Figures S1−S3).
■ BIOCHEMICAL EVALUATION OF SELECTED
PHENYLDIHYDROPYRAZOLONES
As the hit originated from a PDE-focused library and was a
moderately potent human PDE4 and TbrPDEB1 inhibitor, the
possibility that these molecules exert their phenotypic eﬀect via
T. cruzi PDEs was explored. Additionally, compounds were
screened for their activity against TcrCYP51 as the 3-pyridinyl
moiety is a common chemotype for this known drug target.32
Analysis of PDE expression in T. cruzi based on the
transcriptome data of Li et al. show that all ﬁve trypanosome
PDEs (A, B1/B2, C, and D) are expressed in trypamastigotes,
next to TcrCYP51.33 Expression levels of TcrPDEC and
TcrCYP51 do not change more than two-fold after in vitro
infection of human cells, while the mRNA concentrations of
TcrPDEB1 and B2 were signiﬁcantly (log 2 fold-change > 1; q-
value < 0.05) downregulated during the amastigote devel-
opmental stages (Supporting Information Figure S4). In
epimastigotes (insect stage), only TcrPDEC was upregulated
compared to trypomastigotes (log 2 fold-change = 2.7; q-value
= 1.7 × 10−10) (Figure S4).33
As mentioned, PDEB1 and PDEB2 of T. brucei have been
shown to be essential for survival of the parasite.34 While not
much is yet known about the role of the T. cruzi PDEB
enzymes, its homology with the essential PDEB enzymes of T.
brucei led to the hypothesis that TcrPDEB inhibition may be
the underlying mechanism of the phenotypic activity of the
phenyldihydropyrazolones. Therefore, the TcrPDEB1 catalytic
domain was expressed and puriﬁed and selected molecules
from the phenylpyrazolone series were evaluated for inhibitory
potential of this enzyme in an in vitro activity assay (Figure
3A). Overall, the activity was very poor; for example, 3-methyl-
4-pyridinyl-substituted phenylpyrazolone 42 (pIC50 T. cruzi =
6.4) inhibited 11% at 10 μM, while NPD-0227 (34, pIC50 T.
cruzi = 6.4) did not show any TcrPDEB1 inhibition at all,
making it unlikely that this enzyme is responsible for the
observed phenotypic eﬀect.
TcrPDEC was previously reported as a biochemically
validated target by King-Keller et al.; hence, a selection of
phenylpyrazolones was tested for their inhibition of the activity
of the TcrPDEC catalytic domain (a.a. 270−614).29,31 Overall,
the inhibitory activity of the phenyl-dihydropyrazolones
against TcrPDEC-CD proved to be relatively weak (Figure
3B). The most potent phenotypic hits show less than 50%
inhibition of TcrPDEC-CD at 10 μM. For example, 3-methyl-
4-pyridinyl substituted phenylpyrazolone 42 inhibits 49%
(pIC50 T. cruzi = 6.4, Table 1) and NPD-0227 (34) only
21% of TcrPDEC-CD activity (pIC50 T. cruzi = 6.4). The poor
correlation between the phenotypic activity and TcrPDEC-CD
inhibition of this series suggests that this enzyme is also not a
key mediator in the observed phenotypic eﬀect (Figure 3B).
Inhibition of TcrCYP51 has previously been shown to lead
to antiparasitic eﬀects in vitro and in vivo.35−37 Yet, the recent
posacanozole trial suggests that the azole-based TcrCYP51
inhibitor combined with benznidazole is not able to cure
parasitemia.38 These ﬁndings have led to a serious debate on
the validity of TcrCYP51 as drug target.37−44 However, in the
posacanozole trial, the used dosage of the TcrCYP51 inhibitor
only corresponds to 10−20% of the curative dose in mice.39,41
Moreover, the trial also employed a short treatment regimen,
Figure 3. Measured biochemical evaluation activities of selected phenylpyrazolones correlate poorly with the phenotypic activity. (A) TcrPDEB1
inhibition at 10 μM (%) against the phenotypic inhibition on T. cruzi (pIC50). (B) TcrPDEC inhibition at 10 μM (%) against the phenotypic
inhibition on T. cruzi (pIC50). (C) TcrCYP51 inhibition (pIC50) against phenotypic inhibition on T. cruzi (pIC50). Raw data can be found in Table
S1.
Table 4. In Depth in Vitro Parasitology against BT of the Y-Strain (DTU II) and IC Amastigotes of the Tulahuen Strain
(DTUs VI)
cmpnd pIC50 T. cruzi (Tulahuen, IC) (96 h)
a pIC50 T. cruzi (Y-strain, BT) (24 h)
a T. cruzi CYP51 (pIC50)a clog Pb clog Sb TPSA (Å)b
3 5.6 4.9 N.D. 1.3 −2.9 90
30 6.2 4.3 4.3 4.5 −5.9 66
34 6.4 <4.3 6.0 3.4 −4.5 55
36 6.3 4.3 4.0 4.0 −5.5 55
41 6.4 4.3 4.0 4.0 −5.5 55
42 6.2 4.3 4.1 3.6 −4.7 55
57 6.4 4.5 6.0 4.0 −5.1 55
78 6.0 3.9 7.2 4.7 −6.0 55
aAll reported values are within a standard deviation of ±0.2. bclog P, clog P, and TPSA are calculated using CDD Vault.
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whereas it is also known that TcrCYP51 inhibitors are slow
trypanocidal compounds.39,41,42 It has been suggested that with
the design of speciﬁc TcrCYP51 inhibitors, instead of
repurposing fungal CYP51 inhibitors, diﬀerent combination
therapies, or longer treatment regimens, TcrCYP51 inhibition
still has potential.37,41,42,45 In order to investigate whether the
observed antiparasitic eﬀect of the newly identiﬁed hit series is
caused by inhibition of TcrCYP51, a selection of inhibitors was
screened against this enzyme. Gunatilleke et al. reported
commonly observed scaﬀolds in the screening against
TcrCYP51: amongst their top 185 ranked hits, 92 contained
a 3-pyridinyl and 67 contained a 4-pyridinyl moiety, which is
true for most compounds in the phenylpyrazolone series.32
Interestingly, two distinct groups are visible in Figure 3C while
all compounds show phenotypic activity, one group showed
pIC50 values >6.0 against CYP51, while the other group is
virtually inactive. For example, NPD-0227 (34) inhibits
TcrCYP51 with a pIC50 of 6.0 (pIC50 T. cruzi = 6.4), while
4-ﬂuoro-3-pyridinyl substituted phenylpyrazolone 36 (NPD-
0398; pIC50 T. cruzi = 6.3) has a pIC50 of 4.0 on this enzyme
(Figure 3C, Table 4). Also, compounds 30, 41, and 42 are
similarly inactive against TcrCYP51, while still showing a
submicromolar potency against T. cruzi.
■ IN-DEPTH IN VITRO PARASITOLOGICAL
EVALUATION
Next, several of the most active phenylpyrazolones were tested
more in-depth for their antiparasitic action. BT from the Y-
strain (DTU II) and IC amastigotes of the Tulahuen, Y and
Colombiana strains (DTUs VI, II, and I) were used.46 All
compounds show (sub)micromolar activities against the
amastigotes from the Tulahuen strain, but both TcrCYP51
actives (compounds 34, 57, 78, Figure 3C, Table 4) as well as
the inactives 30, 36 (NPD-0398), 41 and 42 (Figure 3C, Table
4) showed a similar drop in activity between the bloodstream
form and the IC forms. Such a diﬀerence in phenotypic activity
is observed more often and has been hypothesized to be an
issue for TcrCYP51 inhibitors.36,47 Yet, in the current
phenylpyrazolone series this diﬀerence in phenotypic activity
is also seen for compounds without TcCYP51 inhibitory
activity. Since all compounds have similar physicochemical
properties (Table 4) and will thus have most likely similar
cellular penetration, another unidentiﬁed mechanism of action
is responsible for the observed phenotypic eﬀects.
Screening of NPD-0227 (34) against the IC form of the
nitro-drug-resistant strains, the Y and Colombiana showed
pIC50’s of 7.0 and 6.3, respectively (Table S3). Also, this
compound did not present a cardiotoxic proﬁle, leading to high
selectivity indexes (SI) when amastigotes from the diﬀerent
strains were assessed inside cardiac cell cultures (Table S3).
■ CONCLUSIONS
By screening a PDE focused library for anti-T. cruzi
compounds, phenyldihydropyrazolone 4 was identiﬁed as a
starting point for further hit optimization. From this structure,
the phenylpyrazolone scaﬀold (5, Figure 2) was derived and
optimized at three diﬀerent positions. Investigation of the R1
position led to the discovery of 3-pyridinyl-phenyldihydropyr-
azolone 34 (NPD-0227) as the best in this series, showing a
pIC50 of 6.4 and 100-fold selectivity over human MRC-5 cells
and >476-fold selectivity over cardiac cell cultures. Although
the SAR investigation on the R2 and R3 positions (5, Figure 2)
yielded useful SAR data, activities did not improve compared
to the initial hit. Screening of a selection of phenylpyrazolones
on TcrPDEC and TcrPDEB1 showed low activities and poor
correlation with phenotypic inhibition, suggesting that neither
of these PDEs is responsible for the observed phenotypic
activity. In vitro screening of phenylpyrazolones against
TcrCYP51 showed both active and inactive compounds.
Parasitic screening of both CYP51 actives (34, 57 and 78)
and inactives (30, 36, 41 and 42) indicates that inhibition of
this enzyme is not responsible for the observed phenotypic
action of this class of compounds. 3-Pyridine 34 (NPD-0227)
shows improved phenotypic activity over the currently used
drug benznidazole (1) on the IC form of the Tulahuen and Y-
strain of T. cruzi (pIC50 = 6.4 and 7.0 respectively) as well as
against the highly nitro-drug-resistant Colombiana strain
(pIC50 = 6.3). The low activity of this series on the
bloodstream form will likely prevent full sterile cure. Additional
research is needed to improve the activity against the
bloodstream form and/or evaluate this class of compounds
for combination therapy against T. cruzi.
■ EXPERIMENTAL SECTION BIOLOGY
CYP51 Assay Protocol. Assay was carried out as described
in Riley et al.30
T. cruzi Cellular Assay. BT of the Y strain of T. cruzi were
obtained by cardiac puncture of infected Swiss Webster mice,
on the parasitemia peak.48,49 For the standard in vitro
susceptibility assay on IC amastigotes, T. cruzi Tulahuen
CL2, β-galactosidase strain (nifurtimox-sensitive), was used.
The strain is maintained on MRC-5SV2 (human lung ﬁbroblast)
cells7 in MEM medium, supplemented with 200 mM L-
glutamine, 16.5 mM NaHCO3, and 5% inactivated fetal calf
serum (FCSi). All cultures and assays are conducted at 37 °C
under an atmosphere of 5% CO2.
MRC-5 Cytotoxicity Cellular Assay. MRC-5 SV2 cells,
originally from a human diploid lung cell line, were cultivated
in MEM, supplemented with L-glutamine (20 mM), 16.5 mM
sodium hydrogen carbonate, and 5% FCS. For the assay, 104
cells/well were seeded onto the test plates containing the
prediluted sample and incubated at 37 °C and 5% CO2 for 72
h. Cell viability was assessed ﬂuorimetrically 4 h after addition
of resazurin (excitation 550 nm, emission 590 nm). The results
are expressed as percentage reduction in cell viability compared
to untreated controls.
Cytotoxicity Assays on Cardiac Cells. Non-infected
primary cardiac cell cultures were incubated at 37 °C for 48 h
with increasing concentrations of each compound diluted in
RPMI. Morphology and spontaneous contractibility were
evaluated by light microscopy, and cellular viability was
determined by PrestoBlue tests.50 The results are expressed
as the diﬀerence in reduction between treated and nontreated
cells according to the manufacturer instructions and the LC50
value (minimum concentration that reduces in 50% the cellular
viability) was determined.50
Trypanocidal Activity. BT from Y strain (5 × 106/mL)
obtained from the blood of Swiss male infected mice (5 × 104
par/animal, ip) at the parasitemia peak were incubated for 24 h
at 37 °C in RPMI in the presence or absence of 1:3 serial
dilutions of the compounds (0−50 μM) for determination of
parasite death rates through the direct quantiﬁcation of live
parasites by light microscopy. The EC50 (minimum compound
concentration that reduces 50% of the number of parasites)
was calculated. The more promising compounds [EC50 ≤
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benznidazole (1)] were evaluated on IC amastigotes of the Y
and Colombiana strains in infected cardiac cell cultures.48 After
24 h infection (10:1 parasite/cell rate), the cultures were
treated for 48 h at 37 °C with nontoxic concentrations of the
compounds. Following the treatment, the cultures were
washed with saline, ﬁxed with Bouin for 5 min, stained with
Giemsa, and evaluated by light microscopy. The percentage of
infected host cells and the number of parasites per cell were
determined for the calculation of the infection index, which
represents the multiplication index using these two parameters,
and then the pIC50 values were determined.
49 SI is expressed
by the ratio between pLC50 (toxicity for mammalian cells) and
the pIC50 (activity on the parasite).
Construction of Plasmids. The catalytic domains of
Tcr(Y)PDEC (aa 270−614) and Tcr(Y)PDEB1 (aa 564−918)
were ampliﬁed by PCR from full length sequences and cloned
(NdeI and XhoI) into the vector pET28a. The sequences were
veriﬁed by sequencing performed by GENEWIZ Inc.
Protein Production. Protein productions of both Tcr(Y)-
PDE_CDs were done following the same protocol. E. coli
BL21(DE3)*pLysS was transformed with either plasmid
pET28aTcr(Y)PDEC_270-614 or pET28aTcr(Y)-
PDEB1_564-918 and the resulting recombinant strains were
grown in 2YT medium at 37 °C. Protein overproduction
overnight at 18 °C was induced with 0.5 mM isopropyl 1-thio-
β-D-galactopyranoside (IPTG) at OD600 = 0.6−0.8. Harvested
cells were resuspended in buﬀer A [20 mM Tris-HCl, pH 8.0,
500 mM NaCl, 20 mM imidazole, 1 mM dithiothreitol
(DTT)] and lysed by one cycle of cell disruption at 25 kpsi.
Protein Puriﬁcation. Protein puriﬁcation was performed
at 4 °C. Cleared lysates were loaded on a 5 mL HisTrap HP
column (GE Healthcare) charged with NiSO4. Unbound
proteins were washed oﬀ with buﬀer A and the protein eluted
with buﬀer A containing 400 mM imidazole and immediately
passed through a HiPrep 26/10 desalting column (GE
Healthcare) equilibrated with 20 mM Tris HCl, pH 8.0, 100
mM NaCl, and 2 mM DTT. Next, the protein was subjected
overnight to Thrombin cleavage (2−10 units per mg of
protein) at 4 °C. Cleaved material was separated from
uncleaved material by passing it through a gravity ﬂow
sepharose column charged with NiSO4 and further puriﬁed by
ion-exchange chromatography on Q Sepharose (5 mL HiTrap
Q HP, GE Healthcare) equilibrated in buﬀer C (50 mM Tris
HCl, pH 8.0, 100 mM NaCl, 1 mM MgCl2, and 1 mM DTT).
The protein was eluted with a linear gradient from 0 to 100%
buﬀer D (50 mM Tris HCl, pH 8.0, 500 mM NaCl, 1 mM
MgCl2, and 1 mM DTT) over 20 column volumes. Aggregates
were removed by gel ﬁltration on a Superdex 200 Increase 10/
300 GL (GE Healthcare) equilibrated in 20 mM Tris HCl, pH
7.5, 100 mM NaCl, 1 mM MgCl2, and 1 mM DTT. A typical
puriﬁcation yielded about 10 mg Tcr(Y)PDEC_CD and 7 mg
Tcr(Y)PDEB1_CDfrom a 1 L cell culture.
TcrPDEB1 and TcrPDEC Activity Assays. PDE activity
assays were performed using the PDELight HTS cAMP
phosphodiesterase kit (Lonza, Walkersville, USA). The assay is
performed at 25 °C in nonbinding, low volume 384 wells
plates (Corning, Kennebunk, ME, USA). PDE activity
measurements (Tcr(Y)PDEC_CD; Km 11.12 μM ± 1.78,
Tcr(Y)PDEB1; Km 2.22 μM ± 0,31) are made in “stimulation
buﬀer” (50 mM Hepes, 100 mM NaCl, 10 mM MgCl, 0.5 mM
EDTA, 0.05 mg/mL BSA, pH 7.5). For each PDE, the optimal
enzyme concentration was determined according to the
manufacturers protocol. Single concentration measurements
are made at 10 μM inhibitor concentration (Triplo measure-
ments/assay, n = 2). Dose−response curves were made in the
range 100 μM to 10 pM (Triplo measurements/assay, n = 3).
Compounds were diluted in dimethyl sulfoxide (DMSO) (ﬁnal
concentration 1%). Inhibitor dilutions (2,5 μL) were trans-
ferred to the 384-wells plate, 2, 5 μL PDE in stimulation buﬀer
is added and mixed, 5 μL cAMP (at 2 × Km up to 20 μM) is
added, and the assay is incubated for 20 min at 300 rpm. The
reaction is terminated by addition of 5 μL Lonza Stop Buﬀer
supplemented with 10 μM NPD-0001. Next, 5 μL of Lonza
Detection reagent (diluted to 80% with reaction buﬀer) is
added, and the reaction incubated for 10 min, shaking 300
rpm. Luminescence was read with a VICTOR3 luminometer
using a 0.1 s/well program.
Relative light units (RLUs) were measured in comparison to
the DMSO-only control; NPD-001 was taken along as positive
control. The Ki values of the inhibitors are represented as the
mean of at least three independent experiments with the
associated standard error of the mean (SEM).
■ EXPERIMENTAL SECTION CHEMISTRY
Chemicals and reagents were obtained from commercial
suppliers and were used without further puriﬁcation.
Anhydrous dimethylformamide (DMF), tetrahydrofuan
(THF), and dichloromethane (DCM) were obtained by
passing them through an activated alumina column prior to
use. Microwave reactions were executed using a Biotage
Initiator microwave system. 1H NMR spectra were recorded
on a Bruker AVANCE 250 (250 MHz), Bruker AVANCE 400
(400 MHz), Bruker AVANCE 500 (500 MHz), or Bruker 600
AVANCE (600 MHz) spectrometer. Data are reported as
follows: chemical shift, integration, multiplicity (s = singlet, d =
doublet, dd = double doublet, t = triplet, dt = double triplet, q
= quartet, p = pentet, h = heptet, bs = broad singlet, m =
multiplet), and coupling constants (Hz). Chemical shifts are
reported in ppm with the natural abundance of deuterium in
the solvent as the internal reference (CDCl3: δ 7.26,
(CD3)2SO: δ 2.50).
13C NMR spectra were recorded on a
Bruker AVANCE 500 (126 MHz) or Bruker AVANCE 600
(150 MHz). Chemical shifts are reported in ppm with the
solvent resonance resulting from incomplete deuteration as the
internal reference (CDCl3: δ 77.16 or (CD3)2SO: δ 39.52).
Systematic names for molecules according to IUPAC rules
were generated using the Chemdraw AutoName program.
Liquid chromatography−mass spectroscopy (LC−MS) data
were gathered using a Shimadzu HPLC/MS workstation with
an LC-20AD pump system, SPD-M20A diode array detector,
and LCMS-2010 EV mass spectrometer. The column used is
an XBridge C18 5 μm column (100 mm × 4.6 mm). Solvents
used were the following: solvent B = ACN, 0.1% formic acid;
solvent A = water, 0.1% formic acid. The analysis was
conducted using a ﬂow rate of 1.0 mL/min, start 5% B, linear
gradient to 90% B in 4.5 min, and then 1.5 min at 90% B, linear
gradient to 5% B in 0.5 min and then 1.5 min at 5% B, total run
time of 8 min. All reported compounds have purities >95%,
measured at 254 nm, unless otherwise mentioned. All high-
resolution mass spectroscopy (HRMS) spectra were recorded
on a Bruker micrOTOF mass spectrometer using electron
spray ionization (ESI) in positive-ion mode. Column
puriﬁcations were either carried out automatically using
Biotage equipment or manually, using 60−200 mesh silica.
Thin-layer chromatography analyses were performed with
Merck F254 alumina silica plates using UV visualization. All
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reactions were done under an N2 atmosphere, unless
speciﬁcally mentioned.
General Methods. General Method A: Synthesis of β-
Keto-esters. Benzoic acid 6 (25 g, 108 mmol) was suspended
in DCM (50 mL) while cooling to 0 °C. Subsequently, oxalyl
dichloride (13.7 mL, 162 mmol) and DMF (0.08 mL, 1.08
mmol) were added and the mixture was allowed to warm up to
room temperature. The mixture was stirred for 2 h after which
volatiles were evaporated. The remaining solids were
redissolved in 50 mL of THF. In a separate ﬂask, methyl
isobutyrate (18.6 mL, 162 mmol) was stirred in THF (50 mL)
at −78 °C and a 2 M lithium di-isopropyl amide (LDA) (65
mL, 130 mmol) was added dropwise while maintaining −78
°C. Upon full addition, the mixture was stirred for 45 min after
which the acid chloride of 6 in THF was added dropwise, again
maintaining the temperature at −78 °C. The reaction was
allowed to warm up to room temperature after which crude
was quenched with water and extracted with diethyl ether. The
organic phase was washed twice with water and once with
brine. The organic layer was then dried with MgSO4, ﬁltered,
and evaporated to dryness. The crude was used in the next step
without further puriﬁcation.
General Method B: Ring Closure of β-Keto-esters. Crude
keto-ester 7 (25 g, 79 mmol) was dissolved in ethanol (75 mL)
and hydrazine hydrate (64%) (38.6 mL, 793 mmol) was
added. The reaction was stirred at room temperature for 48 h
after which white precipitation was visible. To the stirred
solution, 20 mL of water was added to allow further
precipitation, after which solids were ﬁltered oﬀ. Collected
solids were dried in vacuo, yielding the desired product.
General Method C: N-Alkylation of Pyrazolones. Pyr-
azolone 8 (10 g, 34 mmol) was dissolved in dry DMF (25 mL)
and cooled to 0 °C. Sodium hydride (60% in mineral oil) (1.48
g, 37 mmol) was added, and the reaction was stirred for 30 min
at room temperature after which 2-bromopropane (3.54 mL,
38 mmol) was added. The reaction was stirred for 2 h at 50 °C
after which the reaction mixture was quenched with 50 mL of
water. White solids precipitated after quenching, which were
ﬁltered oﬀ and washed with water (2 × 25 mL). The white
solids were dried in vacuo, yielding the target compound as a
white solid. On a small scale (<0.5 g), not all analogues
precipitated after quenching, instead a puriﬁcation over SiO2
was done.
General Method D: Suzuki Coupling. Pyrazolone 11 (1.0 g,
3.0 mmol) and pyridin-3-ylboronic acid (0.54 g, 4.4 mmol)
were charged to a microwave vial after which dimethoxyethane
(DME) (12 mL) and 1 M Na2CO3 (8.84 mL, 8.84 mmol)
were added. The mixture was degassed with N2 for 5 min after
which Pd(dppf)Cl2 (120 mg, 0.15 mmol) was added. The
reaction was then heated in the microwave for 1 h at 120 °C.
The reaction mixture was diluted with MTBE and ﬁltered over
Celite. The residue was washed with saturated NaHCO3 (2×)
and brine (1×). The organic phase was dried over Na2SO4,
ﬁltered, and concentrated in vacuo to be further puriﬁed over
SiO2 using a gradient of 40% EtOAc in heptane toward 60%
EtOAc in heptane. The target compound was obtained as a
white solid.
General Method E: Buchwald Coupling. Pyrazolone 11 (50
mg, 0.15 mmol), piperidine (0.017 mL, 0.18 mmol), Pd2(dba)3
(13 mg, 0.015 mmol), Xantphos (17 mg, 0.029 mmol), and
NatBuO (28 mg, 0.29 mmol) were added to a microwave tube.
The mixture was diluted with dry toluene (2 mL) and degassed
with N2 for 5 min. The mixture was heated in the microwave at
130 °C for 30 min. The reaction mixture was diluted with
MTBE and ﬁltered over Celite. The residue was extracted with
1 M Na2CO3 (2×) and brine (1×) after which the organic
phase was dried over Na2SO4 and concentrated in vacuo. The
remaining crude was puriﬁed over SiO2 using a gradient from
50% EtOAc in n-heptane toward 100% EtOAc, yielding the
desired product as a white solid.
General Method F: Demethylation. Pyrazolone 11 (10 g,
29.5 mmol) was dissolved in dry DCM (50 mL) and mixture
was cooled toward −78 °C. Subsequently, 1 M BBr3 in DCM
(59 mL, 59 mmol) was added dropwise over approximately 30
min. The dry-ice acetone bath was removed and the mixture
allowed to warm toward room temperature and was stirred
overnight. The reaction mixture was then quenched and
diluted with water and extracted with MTBE. The organic
phase was washed with brine (1×) and dried over MgSO4. The
crude was ﬁltered after which remaining volatiles were
evaporated in vacuo. The resulting crude was recrystallized
from a DCM/MTBE mixture, yielding the product as a white
solid.
General Method G: O-Alkylation of Demethylated
Pyrazolones. Pyrazolone 65 (500 mg, 1.5 mmol) was
dissolved in dry DMF (5 mL) and Cs2CO3 (1.0 g, 3.1
mmol) was added followed by (bromomethyl)cyclobutane
(0.19 mL, 1.7 mmol). The reaction mixture was stirred for 3 h
at room temperature after which the mixture was poured in 30
mL of water. The aqueous phase was extracted with EtOAc
after which the organic phase was washed twice with water
followed by brine (1×). The organic phase was dried over
MgSO4, ﬁltered, and evaporated to dryness. The resulting
crude was puriﬁed over SiO2 using a gradient of 20% EtOAc in
heptane toward 50% EtOAc in heptane. Evaporation of pure
fractions yielded the desired product as a white solid.
Below the experimental details of key-compounds 7, 8, 11,
34, 65, 67, and 76 are included, which are representative for
each reaction step. Details as well as the original spectra of all
other compounds can be found in the Supporting Information.
Experimental Data. Methyl 3-(3-Bromo-4-methoxy-
phenyl)-2,2-dimethyl-3-oxopropanoate (7). Prepared accord-
ing to general method A. Crude yield: 38 g. Small portion was
puriﬁed to obtain analysis data. 1H NMR (500 MHz, CDCl3):
δ 8.11 (s, 1H), 7.75 (d, J = 8.7 Hz, 1H), 6.88 (d, J = 8.7 Hz,
1H), 3.95 (s, 3H), 3.65 (s, 3H), 1.52 (s, 6H). 13C NMR (126
MHz, CDCl3): δ 194.9, 175.5, 159.2, 134.4, 129.6, 128.8,
112.1, 110.9, 56.5, 53.0, 52.7, 24.0. LC−MS (ESI) no mass
observed; retention time: 4.84 min.
5-(3-Bromo-4-methoxyphenyl)-4,4-dimethyl-2,4-dihydro-
3H-pyrazol-3-one (8). Prepared according to general method
B starting from crude 7 to aﬀord 22.2 g (75 mmol, 94% over
two steps) of the title compound as a white solid. 1H NMR
(500 MHz, DMSO-d6): δ 11.54 (s, 1H), 7.96 (d, J = 2.2 Hz,
1H), 7.77 (dd, J = 8.6, 2.2 Hz, 1H), 7.16 (d, J = 8.7 Hz, 1H),
3.89 (s, 3H), 1.34 (s, 6H). 13C NMR (126 MHz, DMSO): δ
181.0, 160.6, 156.8, 130.3, 127.3, 125.3, 113.1, 111.8, 56.9,
46.8, 22.3. LC−MS (ESI) m/z: found, 297 [M + H]+;
retention time, 4.51 min.
5-(3-Bromo-4-methoxyphenyl)-2-isopropyl-4,4-dimethyl-
2,4-dihydro-3H-pyrazol-3-one (11). Prepared according to
general method C using 2-bromopropane (0.95 mL, 10 mmol)
to aﬀord 2.0 g (5.9 mmol, 70%) of the title compound as a
white solid. 1H NMR (500 MHz, CDCl3): δ 8.06 (d, J = 2.0
Hz, 1H), 7.68 (dd, J = 9.0 Hz, 2.0 Hz, 1H), 6.91 (d, J = 8.5 Hz,
1H), 4.50 (h, J = 6.5 Hz, 1H), 3.94 (s, 3H), 1.44 (s, 6H), 1.36
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(d, J = 7.0 Hz, 6H). 13C NMR (126 MHz, CDCl3): δ 177.7,
160.1, 156.9, 131.2, 126.5, 125.2, 112.3, 111.5, 56.4, 48.7, 45.3,
22.6, 20.8. LC−MS (ESI) m/z: found, 339 [M + H]+;
retention time, 5.39 min. HRMS-ESI: [M + H]+ calcd for
C15H20BrN2O2
+, 339.0703; found, 339.0700.
2-Isopropyl-5-(4-methoxy-3-(pyridin-3-yl)phenyl)-4,4-di-
methyl-2,4-dihydro-3H-pyrazol-3-one (34). Prepared accord-
ing to general method D using pyridine-3-ylboronic acid (0.47
g, 3.8 mmol) to aﬀord 650 mg (1.93 mmol, 65%) of the title
compound as a white solid. 1H NMR (600 MHz, CDCl3): δ
8.79 (s, 1H), 8.60 (s, 1H), 7.90 (d, J = 7.4 Hz, 1H), 7.83 (d, J
= 2.2 Hz, 1H), 7.78 (dd, J = 8.6, 2.0 Hz, 1H), 7.39 (s, 1H),
7.03 (d, J = 8.7 Hz, 1H), 4.50 (hept, J = 6.7 Hz, 1H), 3.87 (s,
3H), 1.48 (s, 6H), 1.36 (d, J = 6.7 Hz, 6H). 13C NMR (151
MHz, CDCl3): δ 177.7, 161.0, 157.7, 149.8, 147.9, 137.2,
133.9, 128.7, 127.6, 127.5, 124.4, 123.2, 111.2, 55.8, 48.8, 45.3,
22.7, 20.8. LC−MS (ESI) m/z: found, 338 [M + H]+;
retention time, 3.44 min. HRMS-ESI [M + H]+: calcd for
C20H24N3O2
+, 338.1863; found, 338.1851.
5-(3-Bromo-4-hydroxyphenyl)-2-isopropyl-4,4-dimethyl-
2,4-dihydro-3H-pyrazol-3-one (65). Prepared according to
general method F using 1 M BBr3 in DCM to aﬀord 8.2 g (25.2
mmol, 86%) of the title compound as a white solid. 1H NMR
(500 MHz, CDCl3): δ 7.97 (d, J = 2.0 Hz, 1H), 7.64 (dd, J =
8.6, 2.1 Hz, 1H), 7.06 (d, J = 8.6 Hz, 1H), 6.15 (s, 1H), 4.50
(hept, J = 6.7 Hz, 1H), 1.45 (s, 6H), 1.36 (d, J = 6.7 Hz, 6H).
13C NMR (126 MHz, CDCl3): δ 177.8, 160.3, 153.7, 130.1,
127.1, 125.3, 116.2, 110.9, 48.8, 45.4, 22.5, 20.8. LC−MS
(ESI) m/z: found, 325 [M + H]+; retention time, 4.87 min.




yl-2,4-dihydro-3H-pyrazol-3-one (67). Prepared according to
general method G using 2-bromopropane (0.16 mL, 1.7
mmol) to aﬀord 510 mg (1.4 mmol, 90%) of the title
compound as a white solid. 1H NMR (500 MHz, CDCl3): δ
8.02 (d, J = 2.2 Hz, 1H), 7.64 (dd, J = 8.6, 2.2 Hz, 1H), 6.90
(d, J = 8.7 Hz, 1H), 4.60 (hept, J = 6.0 Hz, 1H), 4.48 (hept, J =
6.7 Hz, 1H), 1.43 (s, 6H), 1.39 (d, J = 6.1 Hz, 6H), 1.34 (d, J
= 6.7 Hz, 6H). 13C NMR (126 MHz, CDCl3): δ 177.7, 160.2,
155.6, 131.3, 126.2, 125.0, 114.6, 113.9, 72.1, 48.7, 45.2, 22.6,
22.0, 20.8. LC−MS (ESI) m/z: found, 367 [M + H]+;
retention time, 5.54 min. HRMS-ESI: [M + H]+ calcd for
C17H24BrN2O2, 367.1016; found, 367.1012.
5-(4-Isopropoxy-3-(pyridin-3-yl)phenyl)-2-isopropyl-4,4-
dimethyl-2,4-dihydro-3H-pyrazol-3-one (76). Prepared ac-
cording to general method D using pyridin-3-ylboronic acid
(87 mg, 0.71 mmol) to aﬀord 162 mg (0.44 mmol, 81%) of the
title compound as a transparent oil which solidiﬁed over time.
1H NMR (500 MHz, CDCl3): δ 8.81 (broad singlet, 1H), 8.58
(d, J = 3.8 Hz, 1H), 7.88 (d, J = 7.9 Hz, 1H), 7.82 (d, J = 2.3
Hz, 1H), 7.76 (dd, J = 8.7, 2.3 Hz, 1H), 7.36 (dd, J = 7.8, 4.8
Hz, 1H), 7.02 (d, J = 8.7 Hz, 1H), 4.62 (hept, J = 6.0 Hz, 1H),
4.51 (hept, J = 6.7 Hz, 1H), 1.48 (s, 6H), 1.36 (d, J = 6.7 Hz,
6H), 1.31 (d, J = 6.1 Hz, 6H). 13C NMR (126 MHz, CDCl3):
δ 177.7, 161.1, 156.1, 150.2, 148.1, 136.9, 134.0, 128.8, 128.4,
127.3, 124.0, 122.9, 113.7, 70.8, 48.8, 45.2, 22.7, 21.9, 20.8.
LC−MS (ESI) m/z: found, 366 [M + H]+; retention time,
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as tables of physical chemical properties of synthesized
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properties with parasite growth inhibition; detailed
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■ LIST OF ABBREVIATIONS
a.a., amino acid; bs, broad singlet, BT: bloodstream
trypomastigotes; cAMP, cyclic adenosine monophosphate;
CD, catalytic domain; cGMP, cyclic guanosine mono-
phosphate; clog P, calculated logarithm of the partition-
coeﬃcient; CYP51, cytochorome P450 51; d, doublet; DCM,
dichloromethane; dd, double doublet; DME, dimethoxy-
ethane; dt, double triplet; DTU, discrete typing units; DMF,
dimethyl formamide; dppf , 1 ,1  - ferrocenediy l -b is -
(diphenylphosphine); DTT, dithiothreitol; EDTA, ethyl-
enediaminetetraacetic acid; ESI, electron spray ionization;
EtOAc, ethylacetate; FCS, fetal calf serum; FPMK, fragments
per kilobase of transcript per million mapped reads; q, quartet;
h, heptet; HRMS, high-resolution mass spectroscopy; HTS,
high-throughput screening; Hz, hertz; J, coupling constant; IC,
intracellular; LC−MS, liquid chromatography-mass spectros-
copy; LDA, lithium di-isopropyl amide; m, multiplet; MeOH,
methanol; MHz, megahertz; MRC-5, medical research council
cell strain 5; mRNA, messenger RNA; MTBE, methyl tert-
butyl ether; NMR, nuclear magnetic resonance; p, pentet;
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PDE, phosphodiesterase; q, quartet; RLU, relative light unit; s,
singlet; SAR, structure−activity relationship; SEM, standard
error of the mean; t, triplet; Tbr, Trypanosoma brucei; Tcr,
Trypanosoma cruzi; THF, tetrahydrofuan; TPSA, topical polar
surface area
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